Citations (22)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
John S. Kendrick & Colin Webber. (2022) One small step in time, one giant leap for DMPK kind – a CRO perspective of the evolving core discipline of drug development. Xenobiotica 52:8, pages 797-810.
Read now
Read now
Simon Taylor, James R. J. Gray, Robert Willis, Nigel Deeks, Andrea Haynes, Colin Campbell, Pam Gaskin, Karen Leavens, Emmanuel Demont, Simon Dowell, Jenni Cryan, Mary Morse, Aarti Patel, Helen Garden & Jason Witherington. (2012) The utility of pharmacokinetic–pharmacodynamic modeling in the discovery and optimization of selective S1P1 agonists. Xenobiotica 42:7, pages 671-686.
Read now
Read now
Mario Pellegatti. (2012) Preclinical in vivo ADME studies in drug development: a critical review. Expert Opinion on Drug Metabolism & Toxicology 8:2, pages 161-172.
Read now
Read now
Laura Zonzini, Federica Bianchi, Nicola Cesari & Matteo Sartori. (2010) In vivo rat PK profiling in drug discovery: new challenges. Expert Opinion on Drug Discovery 5:11, pages 1031-1037.
Read now
Read now
Articles from other publishers (18)
Randy R. Miller, Maria Madeira, Harold B. Wood, Wayne M. Geissler, Conrad E. Raab & Iain J. Martin. (2020) Integrating the Impact of Lipophilicity on Potency and Pharmacokinetic Parameters Enables the Use of Diverse Chemical Space during Small Molecule Drug Optimization. Journal of Medicinal Chemistry 63:21, pages 12156-12170.
Crossref
Crossref
Phil Jeffrey & Scott Summerfield. 2017. Pharmacology for Chemists: Drug Discovery in Context. Pharmacology for Chemists: Drug Discovery in Context
316
342
.
Michael D David. (2017) Insecticide ADME for support of early-phase discovery: combining classical and modern techniques. Pest Management Science 73:4, pages 692-699.
Crossref
Crossref
Tugba Copur & Levent Oner. 2017. Nanotechnology Methods for Neurological Diseases and Brain Tumors. Nanotechnology Methods for Neurological Diseases and Brain Tumors
69
89
.
K.G. Pike. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
161
177
.
P. Tosco & M. Mackey. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
253
296
.
M.M. Hann, M.K. Bayliss & A.R. Leach. 2017. Comprehensive Medicinal Chemistry III. Comprehensive Medicinal Chemistry III
560
576
.
Lionel Trottet & Howard Maibach, MDLionel Trottet & Howard Maibach. 2017. Dermal Drug Selection and Development. Dermal Drug Selection and Development
1
13
.
J. Willem M. Nissink, Sebastien Degorce & Ken Page. 2016. Lead Generation. Lead Generation
451
486
.
Ken M. Page. (2016) Validation of Early Human Dose Prediction: A Key Metric for Compound Progression in Drug Discovery. Molecular Pharmaceutics 13:2, pages 609-620.
Crossref
Crossref
Andreas Reichel. 2015. Blood-Brain Barrier in Drug Discovery. Blood-Brain Barrier in Drug Discovery
5
41
.
Marianne Vath, Lizbeth Gallagher, Wilson Shou, Harold Weller, Lisa Elkin & Jun Zhang. (2014) Development of an LC–MS/MS method for high throughput quantification of metformin uptake in transporter inhibition assays. Journal of Chromatography B 967, pages 211-218.
Crossref
Crossref
Ronald E. White. 2014. Handbook of Metabolic Pathways of Xenobiotics. Handbook of Metabolic Pathways of Xenobiotics
1
15
.
Mads H. Rønnest, Felix Nissen, Palle J. Pedersen, Thomas O. Larsen, Walter Mier & Mads H. Clausen. (2013) A Mild Method for Regioselective Labeling of Aromatics with Radioactive Iodine. European Journal of Organic Chemistry 2013:19, pages 3970-3973.
Crossref
Crossref
Chun Li, Bo Liu, Jonathan Chang, Todd Groessl, Matthew Zimmerman, You-Qun He, John Isbell & Tove Tuntland. (2013) A modern in vivo pharmacokinetic paradigm: combining snapshot, rapid and full PK approaches to optimize and expedite early drug discovery. Drug Discovery Today 18:1-2, pages 71-78.
Crossref
Crossref
David Lagorce, Christelle Reynes, Anne‐Claude Camproux, Maria A. Miteva, Olivier Sperandio & Bruno O. Villoutreix. 2011. ADMET for Medicinal Chemists. ADMET for Medicinal Chemists
29
124
.
Andreas Baumann. (2009) Nonclinical development of biopharmaceuticals. Drug Discovery Today 14:23-24, pages 1112-1122.
Crossref
Crossref
Andreas Reichel. (2009) Addressing Central Nervous System (CNS) Penetration in Drug Discovery: Basics and Implications of the Evolving New Concept. Chemistry & Biodiversity 6:11, pages 2030-2049.
Crossref
Crossref